COG-UK

DDN Honored with Multiple Esteemed HPC Awards for Achievements in Supercomputing in Solving the Most Prominent Global Issues

Retrieved on: 
Thursday, November 18, 2021

Gathering, accessing and processing this data quickly is imperative," said Dr. James Coomer, senior VP of products, DDN.

Key Points: 
  • Gathering, accessing and processing this data quickly is imperative," said Dr. James Coomer, senior VP of products, DDN.
  • DDN's 2021 HPCwire Readers' and Editors' Choice Awards include:
    Editors' Choice Best HPC Storage Product or Technology: DDN EXAScaler
    DDN EXAScaler is the most powerful file system for AI, analytics and HPC.
  • DDN extends its leadership in parallel file systems with EXA6 , the foundation for stronger security, enriched data services and end-to-end data management.
  • "Between our worldwide readership of HPC experts and an unparalleled panel of editors, the Readers' and Editors' Choice Awards represent resounding recognition throughout the industry.

Global Genomics Market Research Report 2021: Focus on Functional Genomics & Pathway Analysis - Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 14, 2021

The "Global Genomics Market Size, Share & Trends Analysis Report by Application & Technology (Functional Genomics, Pathway Analysis), by Deliverable (Products, Services), by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Genomics Market Size, Share & Trends Analysis Report by Application & Technology (Functional Genomics, Pathway Analysis), by Deliverable (Products, Services), by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • This has also led to an increase in the market competition, coupled with the development of breakthrough genomic technologies by Veritas Genetics, 23andMe, and other key players.
  • In August 2020, Ancestry launched a new next-generation sequencing-based tool to screen genes linked to blood disorders, colon cancer, heart diseases, and breast cancer.
  • This product, developed by Quest Diagnostics, has a better DNA analysis efficiency when compared to microarray-based testing.